User:Mr. Ibrahem/Treprostinil
From Wikipedia, the free encyclopedia
Treprostinil, sold under the brand names Remodulin among others, is a medication used to treat pulmonary arterial hypertension.[1] It is taken by mouth, injected, or inhaled.[1]
Clinical data | |
---|---|
Trade names | Remodulin, Orenitram, Tyvaso, Trepulmix, others |
AHFS/Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | Subcutaneous, intravenous, inhalation, by mouth |
Drug class | Prostacyclin analog[1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | ~100% |
Metabolism | Substantially metabolized by the liver |
Elimination half-life | 4 hours |
Excretion | Urine (79% of administered dose is excreted as 4% unchanged drug and 64% as identified metabolites); feces (13%) |
Identifiers | |
| |
Chemical and physical data | |
Formula | C23H34O5 |
Molar mass | 390.520 g·mol−1 |
| |
NY (what is this?) (verify) |
Common side effects include headache, nausea, flushing, and pain.[1] Other side effects may include infection, bleeding, and low blood pressure.[1] Safety in pregnancy and breastfeeding is unclear.[2] It is a vasodilator and synthetic analog of prostacyclin.[1]
Treprostinil was approved for medical use in the United States in 2002.[1] In the United States it can only be acquired through a specialty pharmacy.[1] In Europe it was granted orphan designation in 2004.[3] In Canada the injectable formulation cost about 52,000 to 173,000 per year as of 2015.[4] A generic version was approved in 2017.[5]